Modified LR-5 criteria based on gadoxetic acid can improve the sensitivity in the diagnosis of hepatocellular carcinoma

Table 1 Clinical and pathological characteristics of study patients, n (%)

Variables		Values
Number of patients		216
Age (years), mean ± SD		58.69 ± 13.50
Sex	Male	152 (70.4)
	Female	64 (29.6)
Cause of liver disease	HBV	189 (87.5)
	HCV	7 (3.2)
	ALD	8 (3.7)
	NAFLD	2 (0.9)
	SC	5 (2.3)
	Others	5 (2.3)
Number of lesions		244
Size of lesions (cm)		4.51 ± 3.37
Size subgroup	< 20 mm	76 (31.1)
	≥ 20 mm	168 (68.9)
Final diagnosis	HCC	165 (67.6)
	Non-HCC malignancy	24 (9.8)
	Intrahepatic cholangiocarcinoma	17 (7)
	NET G3	3 (1.2)
	Combined hepatocellular-cholangiocarcinoma	2 (0.8)
	Metastasis	2 (0.8)
	Benign lesion	55 (22.5)
	Hemangioma	19 (7.8)
	RN/DN	17 (6.9)
	FNH	9 (3.7)
	Liver abscess	6 (2.5)
	Angiomyolipoma	2 (0.8)
	Nodule of necrosis	1 (0.4)
	Hepatic schistosomiasis	1 (0.4)
Standard reference of diagnosis	Pathologic diagnosis of surgery	117 (48.0)
	Pathologic diagnosis of needle biopsy	85 (34.8)
	Typical imaging features with size stability (2 years)	42 (17.2)
LI-RADS category	LR-1	0 (0)
	LR-2	14 (5.7)
	LR-3	25 (10.2)
	LR-4	68 (27.9)
	LR-5	105 (43.0)
	LR-M	27 (11.1)
	LR-TIV	5 (2.0)

HBV: Hepatitis B; HCV: Hepatitis C; ALD: Alcoholic liver disease; NAFLD: Nonalcoholic fatty liver disease; SC: Schistosomal cirrhosis; NET: Neuroendocrine tumor; RN: Regenerative nodule; DN: Dysplastic nodule; FNH: Focal nodular hyperplasia-like nodule; LI-RADS: Liver Imaging Reporting and Data System.